Conclusion
Adding BEV to traditional front-line or relapse therapy was safe in EOC.
This strategy as maintenance therapy was effective in extending PFS and
OS in advanced-stage patients. Platinum-sensitivity was the strongest
prognostic factor. Platinum-sensitive relapsed EOC patients treated with
BEV-added chemotherapy had a significant improvement in OS and had a
longer duration in progressing to the next progression.
Ethics statement The Institutional Review Board of National
Cheng Kung University Hospital approved the study protocol on 29 April
2019 (ref. no. B-ER-101-318). The study was performed in accordance with
the Declaration of Helsinki. The requirement for informed consent was
waived due to the retrospective nature of the study.
Disclosure of interests YFH got grants from the headquarters of
the University Advancement at the National Cheng Kung University, which
is sponsored by the Ministry of Education, Taiwan, ROC, during the
conduct of the study. None of the funding sources were involved in
collecting, analysing or interpreting data, writing the article or
deciding to submit for publication. The other authors declare no
competing interests. Full disclosure of interests is available to view
online as supporting information.
Acknowledgments This research was carried out and
administratively supported by NCKUH, College of Medicine, National Cheng
Kung University. We acknowledge the efforts made by our nursing
practitioners (Yu Hsiao Tai, Ya-Ting Chen, Ya-Ting Hu, Yueh-Chin Li,
Shu-Jyun Wang, and Ya-Han Tsai) in assessing adverse effects related to
chemotherapy or target therapies.